Chase Leavitt - Oncternal Therapeutics General Secretary
Executive
Chase Leavitt is General Secretary of Oncternal Therapeutics
| Age | 42 |
| Phone | 858 434 1113 |
| Web | https://www.oncternal.com |
Chase Leavitt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chase Leavitt against Oncternal Therapeutics stock is an integral part of due diligence when investing in Oncternal Therapeutics. Chase Leavitt insider activity provides valuable insight into whether Oncternal Therapeutics is net buyers or sellers over its current business cycle. Note, Oncternal Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Oncternal Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chase Leavitt over a year ago Acquisition by Chase Leavitt of 28750 shares of Oncternal Therapeutics at 0.31 subject to Rule 16b-3 |
Oncternal Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7645) % which means that it has lost $0.7645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4986) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Oncternal Therapeutics currently holds 318 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Oncternal Therapeutics has a current ratio of 10.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncternal Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bryan Kadotani | Armata Pharmaceuticals | N/A | |
| Kathleen Borthwick | Passage Bio | 48 | |
| MS MD | Aditxt Inc | N/A | |
| David House | Armata Pharmaceuticals | N/A | |
| Graeme Currie | Pasithea Therapeutics Corp | 58 | |
| DVM MBA | Absci Corp | N/A | |
| Anuj MD | Assembly Biosciences | 47 | |
| Rabia MD | Adverum Biotechnologies | 57 | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| PharmD Mordwinkin | Kezar Life Sciences | 43 | |
| Joe Tedrick | Kezar Life Sciences | N/A | |
| Justine OMalley | Protara Therapeutics | N/A | |
| MS MD | Armata Pharmaceuticals | 50 | |
| Colleen Sjogren | Nuvation Bio | 55 | |
| Heikki Jouttijarvi | Adverum Biotechnologies | N/A | |
| YuWaye MD | CytomX Therapeutics | 57 | |
| Amy CFA | Assembly Biosciences | N/A | |
| Jens Plassmeier | Absci Corp | N/A | |
| Stuart Henderson | Passage Bio | N/A | |
| JD Esq | Passage Bio | 61 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 |
Oncternal Therapeutics Leadership Team
Elected by the shareholders, the Oncternal Therapeutics' board of directors comprises two types of representatives: Oncternal Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncternal. The board's role is to monitor Oncternal Therapeutics' management team and ensure that shareholders' interests are well served. Oncternal Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncternal Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pablo Urbaneja, Senior Development | ||
| Anita Wiseth, Senior Resources | ||
| Gunnar Kaufmann, Chief Officer | ||
| Chase JD, General Secretary | ||
| Salim MD, Chief Officer | ||
| Chase Leavitt, General Secretary | ||
| Steven Hamburger, VP Assurance | ||
| Richard CPA, Treasurer CFO | ||
| Rajesh Krishnan, Chief Officer |
Oncternal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncternal Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 14.21 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.17 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |